Acceleron Pharma, Inc. - Product Pipeline Review - 2015

Published: May, 2015 | Pages: 45 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Acceleron Pharma, Inc. - Product Pipeline Review - 2015

Summary

Global Markets Direct's, 'Acceleron Pharma, Inc. - Product Pipeline Review - 2015', provides an overview of the Acceleron Pharma, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Acceleron Pharma, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Acceleron Pharma, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Acceleron Pharma, Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Acceleron Pharma, Inc.'s pipeline products

Reason to Buy

- Evaluate Acceleron Pharma, Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Acceleron Pharma, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Acceleron Pharma, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Acceleron Pharma, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Acceleron Pharma, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Explore the dormant and discontinued projects of Acceleron Pharma, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Acceleron Pharma, Inc. Snapshot 5
Acceleron Pharma, Inc. Overview 5
Key Information 5
Key Facts 5
Acceleron Pharma, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Acceleron Pharma, Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Acceleron Pharma, Inc. - Pipeline Products Glance 11
Acceleron Pharma, Inc. - Clinical Stage Pipeline Products 11
Phase II Products/Combination Treatment Modalities 11
Phase I Products/Combination Treatment Modalities 12
Acceleron Pharma, Inc. - Early Stage Pipeline Products 13
Preclinical Products/Combination Treatment Modalities 13
Acceleron Pharma, Inc. - Drug Profiles 14
dalantercept 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
luspatercept 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
sotatercept 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
ACE-083 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
ACE-661 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
ACE-772 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
ALKS-693 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Protein for Bone Disorders 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Protein for Fibrosis 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Protein for Muscle Disorders 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Protein for Skin Disease 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Acceleron Pharma, Inc. - Pipeline Analysis 28
Acceleron Pharma, Inc. - Pipeline Products by Target 28
Acceleron Pharma, Inc. - Pipeline Products by Route of Administration 29
Acceleron Pharma, Inc. - Pipeline Products by Molecule Type 30
Acceleron Pharma, Inc. - Pipeline Products by Mechanism of Action 31
Acceleron Pharma, Inc. - Recent Pipeline Updates 32
Acceleron Pharma, Inc. - Dormant Projects 41
Acceleron Pharma, Inc. - Discontinued Pipeline Products 42
Discontinued Pipeline Product Profiles 42
ramatercept 42
Acceleron Pharma, Inc. - Locations And Subsidiaries 43
Head Office 43
Appendix 44
Methodology 44
Coverage 44
Secondary Research 44
Primary Research 44
Expert Panel Validation 44
Contact Us 44
Disclaimer 45

List of Tables

Acceleron Pharma, Inc., Key Information 5
Acceleron Pharma, Inc., Key Facts 5
Acceleron Pharma, Inc. - Pipeline by Indication, 2015 7
Acceleron Pharma, Inc. - Pipeline by Stage of Development, 2015 9
Acceleron Pharma, Inc. - Monotherapy Products in Pipeline, 2015 10
Acceleron Pharma, Inc. - Phase II, 2015 11
Acceleron Pharma, Inc. - Phase I, 2015 12
Acceleron Pharma, Inc. - Preclinical, 2015 13
Acceleron Pharma, Inc. - Pipeline by Target, 2015 28
Acceleron Pharma, Inc. - Pipeline by Route of Administration, 2015 29
Acceleron Pharma, Inc. - Pipeline by Molecule Type, 2015 30
Acceleron Pharma, Inc. - Pipeline Products by Mechanism of Action, 2015 31
Acceleron Pharma, Inc. - Recent Pipeline Updates, 2015 32
Acceleron Pharma, Inc. - Dormant Developmental Projects,2015 41
Acceleron Pharma, Inc. - Discontinued Pipeline Products, 2015 42